|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||10.72 - 10.79|
|52 Week Range||8.90 - 11.15|
|Beta (3Y Monthly)||0.64|
|PE Ratio (TTM)||38.13|
|Forward Dividend & Yield||0.15 (1.40%)|
|1y Target Est||N/A|
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! The simplest way to invest in stocks is to buy exchange traded funds. But in our experience...
Health-care earnings begin in earnest this week. Centene Corp. reported on Tuesday, and Anthem Inc., Biogen Inc., Boston Scientific Corp. and Novartis AG are set to report Wednesday.
The U.S. Food and Drug Administration on Tuesday ordered makers of transvaginal surgical mesh implants to immediately stop their sale and distribution in the United States, the latest action by the agency to tackle safety issues related to the devices. The FDA said Boston Scientific Corp and Coloplast A/S did not demonstrate a reasonable assurance of safety and effectiveness of these devices in their premarket applications. The companies will have 10 days to submit their plan to withdraw these products from the market, the FDA said in a statement https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm636114.htm.
The Food and Drug Administration orders Boston Scientific and Coloplast to stop selling surgical mesh used for some pelvic operations.